$0.72 $0.01 (0.0%)

04:00 PM EDT on 06/26/19

Heat Biologics Inc Com (NASDAQ:HTBX)

CAPS Rating: 1 out of 5

Current Price $0.72 Mkt Cap $40.2M
Open $0.71 P/E Ratio 0.00
Prev. Close $0.72 Div. (Yield) $0.00 (0.0%)
Daily Range $0.71 - $0.78 Volume 5,833
52-Wk Range $0.67 - $1.80 Avg. Daily Vol.

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

11 Outperform
14 Underperform
 

All-Star Players

0 Outperform
9 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:HTBX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.79)
Submitted November 12, 2014

Immunotherapy isn't the greatest corner of the spec biopharma sector to park one's resources long-term, but the stocks tend to cycle with even more volatility than the rest of the sector. Heat Biologics is now much closer to the lower end of its… More

zzlangerhans (99.79)
Submitted June 05, 2016

Lots of crappy biotech companies took advantage of the good times in 2014 and early 2015 to stock their war chests with cash through large dilutive financings. Heat Biologics didn't. In 2016 they've paid the price with a plunging stock and a depleted… More

NASDAQ:HTBX VS S&P 500 (SPY)

NASDAQ:HTBX Summary

Fools bullish on NASDAQ:HTBX are also bullish on:

Fools bearish on NASDAQ:HTBX are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about HTBX.

Recs

2
Member Avatar zzlangerhans (99.79) Submitted: 6/5/2016 9:18:04 AM : Underperform Start Price: $6.50 NASDAQ:HTBX Score: +127.12

Lots of crappy biotech companies took advantage of the good times in 2014 and early 2015 to stock their war chests with cash through large dilutive financings. Heat Biologics didn't. In 2016 they've paid the price with a plunging stock and a depleted bank account as they stagger towards the conclusion of the phase II trial of Vesigenurtacel-L for bladder cancer in Q4. Will they make it without another dilutive financing? I'm guessing not, especially since the results of that skeletonized 16 patient trial are unlikely to reverse Heat's flagging fortunes. Given the weakness of the pipeline and the company's poor financial condition, Heat is a strong candidate for bankruptcy in 2017.

Recs

0
Member Avatar JOhrberg (60.35) Submitted: 3/3/2016 10:42:21 PM : Outperform Start Price: $9.00 NASDAQ:HTBX Score: -137.80

It can't get much lower! Predicting they will have some valuable research to sell, or get bought out.

Leaderboard

Find the members with the highest scoring picks in HTBX.

Score Leader

glenn12345

glenn12345 (99.98) Score: +226.65

The Score Leader is the player with the highest score across all their picks in HTBX.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
MathMan01 < 20 11/4/2013 Underperform 3W $95.90 -99.25% +64.47% +163.72 0 Comment
Slickrick9565 56.67 1/7/2016 Underperform 5Y $41.90 -98.29% +48.77% +147.06 0 Comment
zzlangerhans 99.79 6/1/2016 Underperform 1Y $6.50 -88.95% +38.17% +127.12 1 Comment
Zencyclone 31.11 12/2/2016 Underperform 5Y $12.76 -94.37% +32.11% +126.49 0 Comment
cashsage 98.63 7/14/2017 Underperform 5Y $5.31 -86.46% +18.62% +105.08 0 Comment
ksrinivasan2 91.85 2/1/2018 Underperform 5Y $3.40 -78.87% +3.39% +82.26 0 Comment
RyanIdaho 97.70 7/13/2018 Underperform 1Y $2.37 -69.69% +4.09% +73.79 0 Comment
JoeySolitro1 99.99 1/14/2019 Underperform 5Y $1.38 -47.95% +12.61% +60.55 0 Comment
Fox660Player 99.93 2/26/2019 Underperform 5Y $1.48 -51.47% +3.83% +55.30 0 Comment
dedy2000 75.01 2/12/2019 Underperform 5Y $1.41 -49.06% +6.04% +55.09 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for HTBX.

Advertisement